CMS Unconvinced On PET Scans For Bone Metastasis; CED Data Not Enough
This article was originally published in The Gray Sheet
Executive Summary
While National Oncologic PET Registry data has been effective in persuading CMS to remove evidence-development restrictions from positron emission tomography coverage policies in the past, NOPR data was not enough to support coverage of PET scans to identify bone metastasis in a Dec. 15 national coverage determination.
You may also be interested in...
Bending To Overwhelming Feedback, CMS Softens Stance On PET For Solid Tumors
In a final decision memo released June 11, the Medicare agency provides national coverage for three post-cancer-treatment PET scans. The original coverage proposal would have allowed only one.
Imaging Registry Begins: Coverage-With-Evidence Policy Gets A Second Wind
The May 8 commencement of a nationwide positron emission tomography imaging registry is an important step forward for CMS' fledgling coverage-with-evidence-development (CED) policy, not to mention for expanded use of PET scans
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”